-
Debrisoquin
- indication:For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.
- pharmacologypharmacology:
- mechanism: Debrisoquin acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. In contrast to ganglionic blocking agents, debrisoquin suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, debrisoquin lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.
- toxicity:
- absorprion:
- halflife:
- roouteelimination:
- volumedistribution:
- clearance: